[Treatment of chemotherapy-induced febrile neutropenia in solid tumors].
One of the most dangerous complications of bone marrow suppression due to chemotherapy is febrile neutropenia. The treatment of the affected patients is a multidisciplinary task. In addition to chemotherapy, adequate G-CSF therapy as a primary and secondary prophylaxis can be used to prevent a large part of febrile neutropenic events. Before each chemotherapy cycle, the risk of febrile neutropenia should be evaluated, taking into account the chemotherapeutic combination and patient-specific parameters. Appropriate antibiotic and G-CSF therapy initiated in the course of febrile neutropenia is essential for the success of the therapy. The oncologists can reach treatment success in the patient's therapy if he or she provides the patient the adequate supportive medications at the appropriate time.